Evidence map›Paper›PMID 42359709›Full record

ArticleBiomedical chromatography : BMC2026

Optimized SPE-HPLC-FLD Method for the Simultaneous Determination of Olaparib, Propranolol, and Furosemide in Human Urine.

Georgios Kamaris, Antonia Kalagia, Catherine K Markopoulou

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedical chromatography : BMC, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Georgios KamarisLaboratory of Pharmaceutical Analysis, Department of Pharmacy, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Antonia KalagiaLaboratory of Pharmaceutical Analysis, Department of Pharmacy, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Catherine K MarkopoulouLaboratory of Pharmaceutical Analysis, Department of Pharmacy, Aristotle University of Thessaloniki, Thessaloniki, Greece.ORCID https://orcid.org/0000-0001-7086-681X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Olaparib belongs to the PARP inhibitors and is widely used as an anticancer drug. Due to frequent side effects, it is usually co-administered with an antihypertensive, such as propranolol and/or an antidiuretic, such as furosemide. In this study, a highly sensitive HPLC-FLD method was developed for the simultaneous determination of the three APIs in urine. For their analysis, a Nucleosil C8 column (250 mm × 4.6 mm, 5 μm) at 50°C was used as the stationary phase and an isocratic system of methanol-acetonitrile-20 mM NaH

Indexed as

FurosemidePhthalazinesPiperazinesPropranololSolid Phase ExtractionChromatography, High Pressure LiquidHumansLimit of DetectionLinear ModelsReproducibility of ResultsFurosemideolaparibPhthalazinesPiperazinesPropranololfurosemideolaparibpropranololsolid‐phase extraction (SPE)urine

Identifiers

PMID42359709
PMCPMC13306917

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.